CPAP Could Improve Type 2 Diabetes OSA Patients’ Glycemic Control
American Thoracic Society’s American Journal of Respiratory and Critical Care Medicine.
The research, “Effect of CPAP on glycemic control in patients with obstructive sleep apnea and type 2 diabetes: A randomized clinical trial,” is thought to be the first random controlled trial ever.
Dr. Francisco Garcia-Rio is professor of medicine at Madrid’s Autonoma University and was the senior study author. He said research gave the industry a better understanding of the two major health problems, noting that epidemiological studies were related.
Garcia-Rio said OSA is a huge public health crisis because of the possibility of death associated with it. There have been cases that OSA has led to traffic accidents, neoplastic diseases and cardiovascular complications. He said diabetes mellitus is a worldwide epidemic with nearly 400 million diabetics in the world. The number is expected to rise to 532 million by 2035.
The professor and his colleagues looked at the results from 50, 18 to 80 year-old patients, all of whom at OSA and sub-optimally controlled types 2 diabetes and had been prescribed some kind of CPAP control or intervention. No medications were changed in the trial unless it was deemed medically necessary and patients did not have to change their activity level or diets.
The researchers monitored the glucose control and changes in insulin resistance and sensitivity, and a host of biomarkers that have been linked to type 2 diabetes glycemic control. Researchers discovered that people used CPAP had a significant
- Drop after six months in glycated hemoglobin levels
- Improvement seen at three and six months for insulin sensitivity
- Drop at six months of insulin resistant
CPAP participants also had lower levels in inflammatory molecules IL-1β and IL-16 with higher levels seen in the glucose regulator adiponectin. According to the authors, the studies revealed a one percent drop in HbA1c levels and linked to a 15 to 20 percent drop in huge cardiovascular disease events with another 37 percent drop in microvascular complications associated with diabetes.
If this were to stay true, the authors said the 0.4 percent drop in HbA1c could become an eight percent drop in cardiovascular disease risk and 15 percent drop in microvascular complication risk. The study also revealed a huge decline in LDL cholesterol, which is known to contribute to cardiovascular disease.
Garcia-Rio noted the findings suggest early OSA indications for people who suffer from type 2 diabetes and a valuation for metabolic abnormalities could decrease the chance for cardiovascular disease.